

# Isopropyl Myristate

## 1 Nonproprietary Names

BP: Isopropyl myristate  
PhEur: Isopropylis myristas  
USPNF: Isopropyl myristate

## 2 Synonyms

*Crodamol IPM*; *Estol IPM*; isopropyl ester of myristic acid; *Kessco IPM 95*; *Lexol IPM-NF*; myristic acid isopropyl ester; *Rita IPM*; *Stepan IPM*; *Tegosoft M*; tetradecanoic acid, 1-methylethyl ester; *Waglinol 6014*.

## 3 Chemical Name and CAS Registry Number


1-Methylethyl tetradecanoate [110-27-0]

## 4 Empirical Formula Molecular Weight

$C_{17}H_{34}O_2$

270.51

## 5 Structural Formula



## 6 Functional Category

Emollient; skin penetrant; solvent.

## 7 Applications in Pharmaceutical Formulation or Technology

Isopropyl myristate is a nongreasy emollient that is absorbed readily by the skin. It is used as a component of semisolid bases and as a solvent for many substances applied topically. Applications in topical pharmaceutical and cosmetic formulations include bath oils; make-up; hair and nail care products; creams; lotions; lip products; shaving products; skin lubricants; deodorants; otic suspensions; and vaginal creams; see Table I. For example, isopropyl myristate is a self-emulsifying component of a proposed cold cream formula,<sup>(1)</sup> which is suitable for use as a vehicle for drugs or dermatological actives; it is also used cosmetically in stable mixtures of water and glycerol.<sup>(2)</sup>

Isopropyl myristate is used as a penetration enhancer for transdermal formulations and has been used in conjunction with therapeutic ultrasound and iontophoresis.<sup>(3)</sup> It has been used in a water-oil gel prolonged-release emulsion in which isopropyl myristate is the major ingredient of the oil phase.

Table I: Uses of isopropyl myristate.

Use	Concentration (%)
Detergent	0.003–0.03
Otic suspension	0.024
Perfumes	0.5–2.0
Soap	0.03–0.3
Topical aerosols	2.0–98.0
Topical creams and lotions	1.0–10.0

## 8 Description

Isopropyl myristate is a clear, colorless, practically odorless liquid of low viscosity that congeals at about 3°C. It consists of esters of propan-2-ol and saturated high molecular weight fatty acids, principally myristic acid.

## 9 Pharmacopeial Specifications

See Table II.

Table II: Pharmacopeial specifications for isopropyl myristate.

Test	PhEur 2002	USPNF 20
Identification	+	+
Appearance of solution	+	—
Specific gravity	—	0.846–0.854
Relative density	0.850–0.855	—
Refractive index	1.434–1.437	1.432–1.436
Residue on ignition	—	≤0.1%
Sulfated ash	≤0.1%	—
Acid value	≤1.0	≤1.0
Saponification value	202–212	202–212
Iodine value	≤1.0	≤1.0
Appearance of solution	+	—
Viscosity	5–6 mPa s	—
Water	≤0.1%	—
Organic volatile impurities	—	+
Assay (as $C_{17}H_{34}O_2$ )	≥90.0%	≥90.0%

## 10 Typical Properties

**Boiling point:** 140.2°C at 266 Pa (2 mmHg)

**Flash point:** 153.5°C (closed cup)

**Freezing point:** ≈3°C

**Solubility:** soluble in acetone, chloroform, ethanol, ethyl acetate, fats, fatty alcohols, fixed oils, liquid hydrocarbons, toluene, and waxes. Dissolves many waxes, cholesterol, or lanolin. Practically insoluble in glycerin, glycols, and water.

**Viscosity (dynamic):** 5–7 mPa s (5–7 cP) at 25°C

## 11 Stability and Storage Conditions

Isopropyl myristate is resistant to oxidation and hydrolysis and does not become rancid. It should be stored in a well-closed container in a cool, dry place and protected from light.

## 12 Incompatibilities

When isopropyl myristate comes into contact with rubber, there is a drop in viscosity with concomitant swelling and partial dissolution of the rubber; contact with plastics, e.g. nylon and polyethylene, results in swelling. Isopropyl myristate is incompatible with hard paraffin, producing a granular mixture. It is also incompatible with strong oxidizing agents.

## 13 Method of Manufacture

Isopropyl myristate may be prepared either by the esterification of myristic acid with propan-2-ol or by the reaction of myristoyl chloride and propan-2-ol with the aid of a suitable dehydrochlorinating agent. A high-purity material is also commercially available, produced by enzymatic esterification at low temperature.

## 14 Safety

Isopropyl myristate is widely used in cosmetics and topical pharmaceutical formulations and is generally regarded as a nontoxic and nonirritant material.<sup>(4-6)</sup>

LD<sub>50</sub> (mouse, oral): 49.7 g/kg<sup>(7)</sup>

LD<sub>50</sub> (rabbit, skin): 5 g/kg

## 15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled.

## 16 Regulatory Status

Included in the FDA Inactive Ingredients Guide (otic, topical, and vaginal preparations). Used in nonparenteral medicines licensed in the UK.

## 17 Related Substances

Isopropyl palmitate.

## 18 Comments

The EINECS number for isopropyl myristate is 203-751-4.

## 19 Specific References

- 1 Jimenez SMM, Fresno CMJ, Selles Flores E. Proposal and pharmacotechnical study of a modern dermo-pharmaceutical formulation for cold cream. *Boll Chim Farm* 1996; **135**: 364-373.
- 2 Ayannides CA, Ktistis G. Stability estimation of emulsions of isopropyl myristate in mixtures of water and glycerol. *J Cosmet Sci* 2002; **53**(3): 165-173.
- 3 Fang JY, Fang CL, Huang YB. Transdermal iontophoresis of sodium nonivamide acetate III: combined effect of pretreatment by penetration enhancers. *Int J Pharm* 1997; **149**: 183-195.
- 4 Stenbäck F, Shubik P. Lack of toxicity and carcinogenicity of some commonly used cutaneous agents. *Toxicol Appl Pharmacol* 1974; **30**: 7-13.
- 5 Opdyke DL. Monographs on fragrance raw materials. *Food Cosmet Toxicol* 1976; **14**(4): 307-338.
- 6 Guillot JP, Martini MC, Giauffret JY. Safety evaluation of cosmetic raw materials. *J Soc Cosmet Chem* 1977; **28**: 377-393.
- 7 Lewis RJ, ed. *Sax's Dangerous Properties of Industrial Materials*, 10th edn. New York: Wiley, 2000: 2166.

## 20 General References

- Fitzgerald JE, Kurtz SM, Schardein JL, Kaump DH. Cutaneous and parenteral studies with vehicles containing isopropyl myristate and peanut oil. *Toxicol Appl Pharmacol* 1968; **13**: 448-453.
- Nakhare S, Vyas SP. Prolonged release of rifampicin from internal phase of multiple w/o/w emulsion systems. *Indian J Pharm Sci* 1995; **57**: 71-77.

## 21 Author

AK Taylor.

## 22 Date of Revision

24 June 2002.